US EditionWeight-loss drugs reduce risk of Alzheimer’s, large study shows
- A new study found that GLP-1 medications, used for weight loss and diabetes, reduce the risk of dementia and other neurocognitive disorders by 12%.
- The research showed that users of GLP-1 drugs experienced lower risks for 42 health outcomes but higher risks for 19, including nausea and vomiting.
- The study, which analyzed data from 2.4 million people, noted that results may not apply to all demographics as the majority were older, White, and male.
- Experts suggest further studies are needed to explore the full benefits and risks of GLP-1 medications, emphasizing individualized discussions with healthcare providers.
131 Articles
131 Articles
The Health Risks and Benefits of Weight-Loss Drugs
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine, Dr. Ziyad Al-Aly, chief of research and development at the VA St. Louis Health Care System and clinical epidemiologist at Washington University School of Medicine, and his colleagues performed a comprehensive an…
🔒 FT: Weight-loss drugs reduce risk of Alzheimer’s, large study shows
Key topics GLP-1 drugs like Ozempic reduce Alzheimer’s risk by 12%, study finds. Weight-loss treatments show benefits for 42 conditions, including cognitive health. Risks include higher rates of arthritis, kidney, and pancreatic disorders. Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Register here. The seventh BizNews …
Canadian Affairs
Study shows diabetes drugs' potential beyond weight loss
Read: 3 minA new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.The study published in Nature Medicine is unique in its scope, marking a milestone in the study of new-generation weight-loss drugs such as Ozempic, Wegovy and Mounjaro, which have already somewhat revolutionized the…
Diabetes drug reveals unexpected health benefits
Researchers have found that people who used GLP-1s were less likely to experience 42 health conditions or adverse health events – but more likely to face 19 others. People on Ozempic may have fewer heart attacks, strokes and addictions – but more nausea, vomiting and stomach pain, write LAUREN BALL & EMILY BURCH. Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity. The dramatic effects o…
Coverage Details
Bias Distribution
- 66% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
